Kory H Kitagawa, Robert E Kalb. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal, HumanizedCandidiasis/complicationsCandidiasis/drug therapyCaspofunginColitis/drug therapyColitis/microbiologyColon/microbiologyEchinocandins/therapeutic useFemaleHumansImmunosuppressive Agents/adverse effectsLipopeptidesMiddle AgedOpportunistic Infections/drug therapyOpportunistic Infections/etiologyPsoriasis/complicationsPsoriasis/drug therapy
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedEchinocandinsImmunosuppressive AgentsLipopeptidesCaspofunginefalizumab
Year: 2008 PMID: 19119121 DOI: 10.1016/j.jaad.2008.06.035
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 11.527